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Abstract 
Background: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes 
will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, 
“-omics” approached have enlightened our knowledge of tumor biology. Such approaches have been extensively 
implemented in order to provide biomarkers for monitoring of the disease as well as to improve readouts of thera-
peutic impact. The application of metabolomics to the study of cancer is especially beneficial, since it reflects the bio-
chemical consequences of many cancer type-specific pathophysiological processes. Here, we characterize metabolic 
profiles of colon and ovarian cancer cell lines to provide broader insight into differentiating metabolic processes for 
prospective drug development and clinical screening.
Methods: We applied non-targeted metabolomics-based mass spectroscopy combined with ultrahigh-performance 
liquid chromatography and gas chromatography for the metabolic phenotyping of four cancer cell lines: two from 
colon cancer (HCT15, HCT116) and two from ovarian cancer (OVCAR3, SKOV3). We used the MetaP server for statistical 
data analysis.
Results: A total of 225 metabolites were detected in all four cell lines; 67 of these molecules significantly discrimi-
nated colon cancer from ovarian cancer cells. Metabolic signatures revealed in our study suggest elevated tricar-
boxylic acid cycle and lipid metabolism in ovarian cancer cell lines, as well as increased β-oxidation and urea cycle 
metabolism in colon cancer cell lines.
Conclusions: Our study provides a panel of distinct metabolic fingerprints between colon and ovarian cancer cell 
lines. These may serve as potential drug targets, and now can be evaluated further in primary cells, biofluids, and tis-
sue samples for biomarker purposes.
© 2015 Halama et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The treatment of complex diseases like cancer still 
remains a major challenge, both for patients and for the 
healthcare system. Better characterization of tumor iden-
tity through a comprehensive “-omics” approach has 
modified paradigms in translational cancer research. 
By combining several analyses, major consortiums have 
been driven to describe tumor-specific landscapes. Tran-
scriptomic studies have led to the definition of several 
tumor-specific subtypes, leading to optimal staging as 
well as tailored treatment. Finally, the characterization of 
epigenetic changes has also recently informed clinicians 
about tumor plasticity as a mechanism that supports 
therapeutic escape. Aside from the large body of clini-
cal work, most of these novel techniques have been opti-
mized using model cancer cell lines. The use of model 
cell lines has clearly culminated in the cancer cell line 
encyclopedia (CCLE) project, in which multiple cancer 
cell lines have been characterized in detail using several 
“-omics” platforms.
Metabolomics is the study of the small molecule com-
position (metabolites <2,000  Da) in bio-fluids, tissue 
samples, and cell lines. By measuring the consequences 
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of all changes in gene expression, protein abundance, and 
environmental influence, metabolomics has been recog-
nized as the “-omics” technology that provides readouts 
that are closest to the clinical endpoint [1]. Metabolomics 
approaches based on high-throughput technologies, 
mostly including mass spectrometry [e.g., liquid chro-
matography–mass spectrometry (LC–MS), ultrahigh-
performance liquid chromatography–mass spectrometry 
(UPLC–MS), or gas chromatography–mass spectrometry 
(GC–MS) or nuclear magnetic resonance spectroscopy 
(NMR)] tools, have recently become the main strategies 
for identifying novel biomarkers and elucidating the eti-
ology of complex diseases, foremost diabetes [2] and can-
cer [3]. There are still several open questions in the field 
of complex disorders that can be addressed by applying 
metabolomics. For instance, it has been reported that 
the ovary is a site of metastasis for several cancer types, 
and particularly colorectal cancer [4]. Nevertheless, dif-
ferentiation between primary ovarian tumors and ovar-
ian metastases that originate from primary colon tumors 
is difficult with available radiological approaches, and 
can remain confusing after histopathological analysis. 
Assays that enable clear differentiation between primary 
ovarian tumor and ovarian metastasis from tissue or bio-
fluids samples could strongly support correct diagno-
sis and patients’ outcomes. This issue has already been 
addressed using genomics, proteomics, and tissue array 
profiling approaches, and enables the determination of 
tissue-specific patterns [5]. We believe that determining 
which metabolic markers present in biofluids are able to 
differentiate between primary ovarian tumor and ovarian 
metastasis from colon tumors could improve diagnostic 
capability.
Metabolomics has already been used to identify bio-
markers of ovarian and colon carcinomas in plasma [6, 7] 
and tissue samples [8, 9]; however, these reports focus on 
biomarkers that differentiate cases from controls, rather 
than cancers from different origins. Additionally, human 
biofluids are not an optimal matrix for study when 
attempting to identify and understand metabolic patterns 
from two different cancer types, because several factors 
(e.g., age, gender, or daily habits) might have a strong 
impact on whole-body metabolism and overshadow pat-
terns of interest. Metabolic studies in cell culture are 
highly valuable [10] to identify functional biomarkers 
that represent cellular processes [11–13] or cancer cell 
lines’ individuality [12, 14, 15], and are essential for a 
comprehensive understanding of cell biology and to com-
plement clinical studies [10].
The main goal of this study was to determine the met-
abolic signatures of colon and ovarian cancer cell lines, 
which might serve several purposes. First, we endeav-
ored to determine the metabolic signatures of ovarian 
and colon cancer cell lines, which could be evaluated in 
greater detail to determine metabolic fingerprints for cell 
identity purposes. The identified metabolic signatures 
and pathways will provide insight into the pathophysi-
ology of ovarian and colon cancer cell lines. Second, we 
attempted to identify metabolic processes and pathways 
that distinguish ovarian and colon carcinomas that might 
be targetable to control neoplastic disease, with potential 
clinical applications. We applied non-targeted metabo-
lomics to profile four different cell lines from colorectal 
(HCT15, HCT116) and ovarian (OVCAR3, SKOV3). We 
identified metabolic signatures and pathways that clearly 
demonstrated differences between the two tumor types.
Methods
Cell culture
Established cancer cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas, 
VA, USA). Upon receipt, cells were expanded; at <10 
passages, aliquots of cells were stored frozen in liquid 
nitrogen. Cells from an aliquot were kept in culture for 
<2  months. Human ovarian adenocarcinoma cell lines 
SKOV3 (HTB-77) and OVCAR3 (HTB-161) were grown 
in Dulbecco’s modified Eagle medium high glucose 
(Hyclone, Thermo Scientific) supplemented with 10% 
fetal bovine serum (FBS; Hyclone, Thermo Scientific), 1% 
penicillin–streptomycin solution (Sigma), 2  mM l-glu-
tamine (Sigma), 1× non-essential amino acids (Hyclone, 
Thermo Scientific). The human colorectal adenocarci-
noma cell lines HCT15 (ATCC CCL 225) and HCT116 
(CCL247) were maintained in McCoy’s 5A medium sup-
plemented with 10% heat-inactivated FBS, 2  mM l-glu-
tamine, and 1% penicillin–streptomycin solution. For 
the experiments, cells were trypsinized and washed with 
PBS, and all cell lines were cultivated in M199 medium 
to avoid the effect of culture milieu on metabolic pro-
file. After incubation overnight, cells were thoroughly 
washed, medium was changed, and cells were cultivated 
in fresh medium for the next 24  h. Once cells reached 
80% confluence (approximately 48  h after cell were 
seeded), samples were collected by trypsinization. One 
million cells were counted and washed with PBS; cell pel-
lets were frozen at −80°C. Ten replicates were prepared 
for each cell line.
Sample preparation for metabolic profiling
Frozen pellets were sent to Metabolon Inc. (Durham, NC, 
USA) for metabolic profiling, where all procedures were 
performed according to Metabolon’s standard protocols. 
All samples were maintained at −80°C after processing 
with the MicroLab STAR® system from Hamilton Com-
pany. In a first step recovery standards were added for 
quality control (QC) purposes. Samples were extracted 
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with series of organic and aqueous solvents to remove 
the protein fraction, allowing the maximum recovery of 
small molecules (metabolites). Each sample extract was 
split into equal parts for GC and LC analysis. After the 
removal of organic solvent, samples were frozen and 
vacuum-dried.
Metabolite measurements with UPLC–MS
Each sample extract designated for LC–MS analysis was 
split into two aliquots, dried, and reconstituted in acidic 
or basic LC-compatible solvents, each of which contained 
eight or more injection standards at fixed concentra-
tions to ensure injection and chromatographic consist-
ency. The analysis of LC/MS samples performed on the 
platform using a Waters ACQUITY UPLC system and a 
Thermo Fisher Scientific Orbitrap Elite high resolution/
accurate mass spectrometer, which was composed of 
a heated electrospray ionization (HESI) source and an 
orbitrap mass analyzer operating at 30,000 mass resolu-
tion. Samples were analyzed using acidic positive ion 
optimized conditions (one aliquot) and basic negative ion 
optimized conditions (second aliquot) in two independ-
ent injections on separate dedicated columns. Extracts 
reconstituted in acidic conditions were gradient eluted 
using water and methanol containing 0.1% formic acid, 
while the basic extracts used water/methanol containing 
6.5 mM ammonium bicarbonate. The MS analysis alter-
nated between MS and data-dependent MS2 scans using 
dynamic exclusion.
Metabolite measurements with GC–MS
Samples assigned for GC–MS analysis were re-dried 
under vacuum for at least 24  h prior to derivatization. 
The derivatization process was performed using N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) under 
dried nitrogen conditions. The GC column was 5% phe-
nyl, and the temperature ramp was from 40 to 300°C over 
a 16-min span. The measurements were performed on a 
Thermo-Finnigan Trace DSQ fast-scanning single-quad-
rupole mass spectrometer instrument using electron 
impact ionization, which was tuned and calibrated daily 
for mass resolution and mass accuracy.
Metabolite identification
Peaks obtained after measurements were identified using 
Metabolon’s propriety peak integration software, and 
component parts were stored in a separated and spe-
cifically designed complex data structure. Metabolites 
were identified by comparing the obtained data to the 
library entries of purified standards or unknown recur-
rent entities. On the date of data evaluation, more than 
3,000 commercially available purified standard com-
pounds were acquired and registered in the Laboratory 
Information Management System (LIMS) for distribu-
tion to both LC and GC platforms for the determination 
of their analytical characteristics. The combination of 
chromatographic properties and mass spectra provided 
an indication of a match to the specific compound or iso-
baric entity. To achieve the highest data quality for statis-
tical analysis, series of QC and curation processes were 
conducted. This system enables accurate and consistent 
identification of true chemical entities with simultane-
ous removal of system artifacts, mis-assignments, and 
background noise. Library matches for each compound 
were checked for each sample, and manually corrected if 
necessary.
Because sample measurements were obtained during a 
5-day period, data were normalized to correct variations 
resulting from inter-day tuning differences in the instru-
ment. Essentially, each compound was corrected in a 
run-day by registering the medians to equal one, propor-
tionally normalizing each data point.
Metabolomics data
In total, we identified 533 metabolites, including 435 
metabolites of known identity and 98 molecules of 
unknown identity. The median number of metabolites 
detected in any single sample in the whole data set was 
405, the median number of metabolites detected in a 
single sample per cell line were as follows: HCT15, 372; 
HCT116, 391; OVCAR, 438; SKOV3, 467. Metabolites 
with >20% missing (N = 308) values were removed from 
the data set, and metabolites with <20% missing values 
(N = 225) were imputed to the average in the group.
Statistical data analysis
Statistical data analysis was performed using the web-
based tool metaP-server at the Helmholtz Center Munich 
(http://metabolomics.helmholtz-muenchen.de/metap3), 
which provides automated and standardized data analy-
sis for quantitative metabolomics data [16]. The server 
calculates general statistical measures for the metabolite 
quantifications, including mean, median, and, standard 
deviation in relation to the mean; it also provides prin-
cipal component analysis (PCA), hypothesis tests, and 
correlation analysis [16]. For visualization, metaP-server 
creates PCA plots, bar plots, and box plots [16].
Metabolic data was normalized against cell number 
(1  ×  106 cells). PCA was applied to identify outliers. 
Two outliers in the SKOV3 cell line were identified and 
removed, possibly caused by some non-traceable experi-
mental or technical errors (Additional file 1: Figure S1).
The non-parametric Kruskal–Wallis test for multi-class 
categorical phenotypes was applied to test the associa-
tion of metabolite concentration with cell line. We used 
the Mann–Whitney, non-parametric hypothesis test for 
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two-class phenotype. Metabolites that enable differentia-
tion between cancer types were identified based on the 
following criteria: significant difference between ovar-
ian and colon cell lines (p < 2.22 × 10−4 for comparison 
HCT116 + HCT15 vs. OVCAR3 + SCOV3), but no dif-
ferences within groups of cell lines from the same origin, 
(p > 2.22 × 10−4 for HCT116 vs. HCT15 and OVCAR3 
vs. SCOV3).
We adopted the most conservative approach to infer-
ring significant differences between cancer types; 
statistical significance between cancer types and 
between cell lines was inferred using stringent Bon-
ferroni correction to account for testing 225 metabo-
lites (p < 0.05/225 = 2.22 × 10−4). The full data set and 
metaP analysis are freely and fully available at the follow-
ing websites: ovarian vs. colon: http://metap.helmholtz-
muenchen.de/metap3/run.cgi?ID=1415435214597630; 
HTC15 vs. HTC116: http://metap.helmholtz-muenchen.
de/metap3/run.cgi?ID=1415362867314825; SKOV3 vs. 
OVCAR: http://metap.helmholtz-muenchen.de/metap3/
run.cgi?ID=1415431362747244; all cell lines HTC15, 
HTC116, OVCAR3, and SKOV3: http://metap.helmholtz-
muenchen.de/metap3/run.cgi?ID=141536220398464.
Hierarchical clustering (HCL) was performed using 
the MultiExperiment Viewer (MeV) v. 4.9 software [17], 
based on log-scaled and z-scored data, Pearson cor-
relation as a distance measure, and average linkage 
clustering.
Results
Overall metabolic signatures of colon and ovarian cancer 
cell lines
We applied non-targeted metabolomics in order to deter-
mine the metabolic signatures of four widely used cancer 
cell lines, two from colorectal carcinoma (HCT15 and 
HTC116) and two from ovarian carcinoma (OVCAR3 
and SKOV3). The obtained dataset resulted in 225 indi-
vidual metabolites, which in turn were used in the anal-
ysis (see Additional file  2: Table  S1 for a full list of all 
metabolites). PCA revealed clear separation between 
the four cell lines, with a tight clustering of biological 
replicates (Figure  1), confirming their strong metabolic 
diversity.
To provide broader insight into the data set, we applied 
bidirectional hierarchical cluster analysis to all 225 
metabolites (Figure  2a). All samples were split at the 
highest level by cancer type, and at a second level by cell 
line, with biological replicates clustering closely together. 
Metabolites clustered into four major groups according 
to their patterns; these groups exhibited alterations spe-
cific to: each cell line, cell lines from different origins as 
well as cell lines from a common origin. Examples of cell 
line-specific metabolites are presented as box plots in 
Additional file 3: Figure S2. Comparison of the metabolic 
profiles of cell lines from the same origin (OVCAR3 vs. 
SKOV3 and HCT15 vs. HCT116) resulted in the identifi-
cation of 105 metabolites that significantly differentiated 
OVCAR3 from SKOV3 (Additional file 4: Table S2) and 
48 metabolites that significantly differentiated HCT15 
from HCT116 (Additional file 5: Table S3).
Metabolites that differentiated colon from ovarian cancer 
cell lines
To identify metabolites that are specifically related 
to cancer cells’ origin (colon vs. ovary), we identified 
molecules that differed significantly between ovar-
ian and colon cell lines (p  <  2.22  ×  10−4 for compari-
son of HCT116 + HCT15 vs. OVCAR3 + SCOV3), but 
not within groups of cell lines from a common origin 
(p > 2.22 × 10−4 for HCT116 vs. HCT15 and OVCAR3 
Figure 1 Metabolic diversity of the examined cell lines. The PCA score plots demonstrate distinct clustering of HCT15 (dark blue), HCT116 (light 
blue), OVCAR3 (red), and SKOV3 (orange). Clear separation of cell lines was observed. The number of dots corresponds to the number of repli-
cates. Data was analyzed using the metaP server [16] and can be accessed interactively at http://metap.helmholtz-muenchen.de/metap3/run.
cgi?ID=141536220398464.
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Figure 2 A heat map of the metabolite profiles. a Colour coding displays differences between cell lines: green indicates lower levels and red 
indicates higher levels of metabolite intensity (z-scored data). Samples are indicated by blue color gradation for colon cancer cell lines (HCT15, dark 
blue; HCT116, light blue), and red and orange color gradation for ovarian cancer cell lines (OVCAR3, red; SKOV3, orange). Metabolites that significantly 
differentiate colon from ovarian cancer cell lines are framed. The blue frame indicates metabolites detected at higher levels in colon cancer cell lines; 
the red frames indicate metabolites observed at higher levels in ovarian cancer cell lines. b Exemplified model of patterns investigated across the 
metabolites for identification of molecules differentiating colon from ovarian carcinomas.
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vs. SCOV3) (Figure 2b). We identified 67 metabolites that 
follow this pattern (Table 1). Because we compared met-
abolic signatures of ovarian and colon cancer cell lines, 
the term significantly higher or lower, in this manuscript, 
refers to the significant difference in metabolic signature 
when comparing one group versus another.
Metabolites differentiating colon from ovarian cancer 
cell lines were grouped into different metabolic classes 
including amino acids, carbohydrates, energy-related 
metabolites, lipids, nucleotides, dipeptides, and xenobi-
otics (Table 1). Nine of the 67 metabolites that differenti-
ated ovarian versus colon cancer cell lines were unknown. 
The majority of metabolites were significantly higher in 
ovarian cancer cell lines than in colon cancer cell lines 
(Table  1). In general, ovarian cancer cells displayed sig-
nificantly higher levels of amino acids, dipeptides (Addi-
tional file  6: Figure  S3), lipids, and tricarboxylic acid 
(TCA) cycle intermediates; colon cancer cell lines exhib-
ited higher levels of carnitine and biogenic amines. The 
metabolites that differentiated colon from ovarian cancer 
cell lines are highlighted in Figure  2a. They are distrib-
uted among the first, second, and fourth clusters.
Metabolic pathways active in colon and ovarian  
cancer cell lines
We reconstructed a metabolic pathway based on the 
metabolites that significantly differentiated colon from 
ovarian cancer cell lines, along with other metabolites 
identified in the data set that are relevant to these path-
ways (Additional file  7: Figure  S4, and synthesized in 
Figure 3a).
As presented in the Additional file 7: Figure S4, glucose 
levels differed strongly between cell lines and were not 
cancer type-specific. However, glucose-6-phosphate and 
mannose-6-phosphate levels were higher in both ovarian 
cancer cell lines, which suggest higher glycolytic activ-
ity in comparison to colon cancer cell lines. Lactate was 
highest in the SKOV3 line, while OVCAR3 exhibited only 
slight lactate elevation in comparison to colon cancer cell 
lines.
Levels of TCA cycle intermediates, including succinate, 
fumarate, and malate, were higher in ovarian cell lines, 
clearly differentiating them from colon cancer cell lines. 
The levels of the branched chain amino acids (BCAA) 
isoleucine and valine and the aromatic amino acids 
(AAA) tyrosine and phenylalanine were higher in ovarian 
cancer cell lines. BCAAs can be catabolized to propionyl-
CoA, and then to methylmalonyl-CoA and succinyl-CoA, 
which in turn can be incorporated into the TCA cycle. In 
addition, phenylalanine and tyrosine can enter the TCA 
cycle after conversion to fumarate (Figure  3a). Colon 
cancer cell lines exhibited higher levels of isovalerylcar-
nitine and isobutyrylcarnitine (degradation products of 
isoleucine and valine, respectively) than ovarian cancer 
cells.
Fatty acid (FA) and glycerophospholipid (GPL) signa-
tures strongly differentiated colon from ovarian cancer 
cell lines, but are similar between cell lines of a shared 
origin (Additional file  7: Figure  S4). FA and GPL levels 
were significantly lower in colon cancer cell lines, sug-
gesting a release of GPLs from the cellular membrane 
and further catabolism to FAs. FAs can then be degraded 
during the process of β-oxidation, which occurs in the 
mitochondria. Because FAs cannot migrate into the 
mitochondrial matrix across the mitochondrial mem-
brane alone, long-chain acyl groups bind to carnitines, 
which serve as a carrier. Accordingly, levels of deoxycar-
nitine (a carnitine precursor) and other short-chain acyl-
carnitines were higher in colon cancer cell lines.
Ovarian cancer cell lines exhibit higher levels of FAs 
and GPLs (seven glycerophosphoethanolamines and 
two glycerophosphoinositols), which suggests the de 
novo synthesis and elongation of FAs and GPLs (which 
requires the acetyl-CoA molecule), as well as their accu-
mulation. Because citrate serves as an acetyl-CoA donor 
for FA synthesis and elongation [18] and GPLs are com-
posed of FA molecules, higher lipid metabolism might 
be connected with increased TCA cycle metabolism in 
ovarian cancer cell lines. Significantly higher levels of 
linoleate (18:2 n6) and dihomo-γ-linoleate (20:3 n6) in 
ovarian cancer cell lines might indicate the subsequent 
desaturation of linoleate (catalyzed by delta-6-desaturase) 
followed by its further elongation to dihomo-γ-linoleate 
(catalyzed by elongase-5) (Additional file  7: Figure  S4). 
The ovarian cancer cell lines exhibited elevated methio-
nine metabolism, as shown by significantly higher levels 
of methionine, N-acetyl-methionine, methionine sulfox-
ide, cystathionine, and dimethylarginine.
Among the urea cycle intermediates, the level of cit-
rulline was higher in ovarian cancer cell lines. Other 
metabolites connected to the urea cycle were higher 
in colon cancer- cell lines, such as N-acetylputrescine, 
beta-alanine (both products of putrescine metabo-
lism), and trans-4-hydroxyproline (a product of proline 
metabolism).
Discussion
Metabolic differences between cancer cells and healthy 
cells were recognized by Warburg as early as the 1920s 
[19]. Modern metabolomics tools are able to capture 
overall metabolite composition in different types of sam-
ples. In comparison to healthy cells, the metabolism of 
cancer cells is generally characterized by elevated catabo-
lism of glucose into lactate, known as the Warburg effect 
[19], as well as the preferential metabolism of amino 
acids, including valine, isoleucine, and glutamine [20, 
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Table 1 Metabolites that distinguish colon cancer cell lines from ovarian cancer cell lines
Metabolic group/metabolites Ovarian-colon Levels in ovary HCT15_HCT116 SKOV3_OVCAR3
p value p value p value
Amino acid metabolism
Citrulline 5.48 × 10−7 Higher 0.0433 0.0003
Cystathionine 5.96 × 10−11 Higher 0.1051 0.0676
Dimethylarginine (SDMA + ADMA) 2.08 × 10−7 Higher 0.2176 0.0545
Histidine 1.61 × 10−7 Higher 0.1230 0.6965
Isoleucine 1.13 × 10−9 Higher 0.2475 0.0003
Methionine 5.96 × 10−11 Higher 0.7959 0.0343
Methionine sulfoxide 1.79 × 10−9 Higher 0.0011 0.0021
N-acetylmethionine 1.79 × 10−9 Higher 0.4813 1.0000
N-acetylputrescine 1.54 × 10−7 Lower 0.2176 0.2133
N6-acetyllysine 4.17 × 10−10 Higher 0.0015 0.0676
Phenylacetylglycine 1.52 × 10−7 Lower 0.1431 0.0043
Phenylalanine 5.96 × 10−11 Higher 0.5288 0.0031
Tyrosine 5.96 × 10−11 Higher 0.2799 0.0434
Valine 5.96 × 10−11 Higher 0.7959 0.0009
Carbohydrate
Isobar: ribulose 5-phosphate, xylulose 5-phosphate 0.000172 Higher 0.0412 0.0003
Mannose-6-phosphate 1.54 × 10−7 Higher 0.6230 0.0005
UDP-glucuronate 5.96 × 10−11 Higher 0.0052 0.3599
Cofactors and vitamins
Thiamin (Vitamin B1) 1.54 × 10−7 Higher 0.0101 0.0044
Energy
Fumarate 2.08 × 10−7 Higher 0.0068 0.0343
Malate 1.63 × 10−5 Higher 0.6305 0.1728
Succinate 5.96 × 10−11 Higher 0.6842 0.0003
Lipids
1-Arachidonoylglycerophosphoethanolamine 1.13 × 10−9 Higher 0.2475 0.1011
1-Docosahexaenoylglycerophosphoethanolamine 3.77 × 10−5 Higher 0.9118 0.0434
1-Palmitoylglycerophosphoethanolamine 0.000128 Higher 0.1230 0.0085
1-Palmitoylglycerophosphoinositol 1.16 × 10−8 Higher 0.7959 0.4598
1-Stearoylglycerophosphoethanolamine 5.49 × 10−6 Higher 0.0892 0.0044
1-Stearoylglycerophosphoinositol 1.24 × 10−5 Higher 0.0756 0.2743
2-Arachidonoylglycerophosphoethanolamine 8.28 × 10−9 Higher 0.9705 0.0085
2-Docosahexaenoylglycerophosphoethanolamine 1.15 × 10−5 Higher 0.0433 0.0031
2-Linoleoylglycerophosphoethanolamine 1.75 × 10−6 Higher 0.5966 0.1728
Butyrylcarnitine 4.53 × 10−6 Lower 0.2176 0.0003
Deoxycarnitine 0.000023 Lower 0.0003 0.5726
Dihomo-linoleate (20:2n6) 5.96 × 10−11 Higher 0.6842 0.2370
Dihomo-linolenate (20:3n3 or n6) 5.96 × 10−11 Higher 0.1431 0.0062
Glycerol 3-phosphate (G3P) 5.96 × 10−11 Higher 0.5787 0.0266
Linoleate (18:2n6) 5.96 × 10−11 Higher 0.6305 0.0831
Mead acid (20:3n9) 5.96 × 10−11 Higher 0.2799 0.0021
Myo-inositol 5.96 × 10−11 Higher 0.6842 0.0062
Scyllo-inositol 5.96 × 10−11 Higher 0.7959 0.6965
Nucleotide
Guanosine 5′- monophosphate (5′-GMP) 6.89 × 10−7 Higher 0.0185 0.6334
Peptide
Alanylleucine 1.79 × 10−9 Higher 0.3527 0.0003
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21]. Furthermore, the analysis of 22 diverse tumor types 
revealed significant heterogeneity in the activity of sev-
eral metabolic pathways (e.g., oxidative phosphorylation 
and the TCA cycle) [22], suggesting tumor-specific meta-
bolic differences  [23–25]. Thus, metabolic differences 
among cancers of various origins could be applied to dif-
ferentiate between primary ovarian cancer and ovarian 
metastases of colon origin, which have historically been 
very difficult to distinguish using available radiological 
and histological approaches. To evaluate this concept, 
we applied non-targeted metabolomics to four cell lines 
derived from colon and ovarian cancers.
Among the 225 metabolites analyzed in this study, we 
found strong metabolic individuality among the different 
cell lines, with concomitant identity in lines with a shared 
tissue of origin (colon vs. ovary). To ensure robustness, 
we normalized metabolic data on cell number as 
described previously [12, 13]; we excluded normalization 
against protein content, because it has been reported that 
this strategy introduces large errors into the data set [26].
We have found 67 metabolites that significantly dif-
ferentiate colon from ovarian cancer cell lines, sup-
porting the idea that cancers originating from different 
tissues can be metabolically distinct. These findings are 
preliminary and cannot be directly translated to clinical 
applications, and validation in human tissue and bioflu-
ids samples is required; however, we compared our data 
with previous reports comparing healthy controls with 
colorectal or ovarian cancer patients. Interestingly, our 
findings were concordant with those of previous stud-
ies reporting differences in metabolites and metabolic 
pathways in biofluids and tissue samples (Figure  3b). 
Sixty-seven metabolites were identified that significantly differentiated colon cancer cell lines from ovarian cancer cell lines according to following criteria: significant 
difference between ovarian and colon cell lines (p < 2.22 × 10−4  for comparison of HCT116 + HCT15 vs. OVCAR3 + SCOV3), but no differences between cell lines of 
the same origin, (p > 2.22 × 10−4 for HCT116 vs. HCT15 and OVCAR3 vs. SCOV3). P values were calculated with metaP server using the Mann–Whitney test.
Table 1 continued
Metabolic group/metabolites Ovarian-colon Levels in ovary HCT15_HCT116 SKOV3_OVCAR3
p value p value p value
Glycylglycine 5.96 × 10−11 Higher 0.0524 0.2743
Glycylleucine 5.96 × 10−11 Higher 0.0007 0.1220
Leucylaspartate 5.96 × 10−11 Higher 0.7394 0.0545
Leucylglutamate 2.28 × 10−7 Higher 0.2475 0.0005
Leucylglycine 5.78 × 10−9 Higher 0.2176 0.0205
Phenylalanylglycine 5.96 × 10−11 Higher 0.0005 0.0044
Phenylalanylserine 7.22 × 10−8 Higher 0.1051 0.0031
Prolylalanine 2.68 × 10−9 Higher 0.5288 0.6334
Prolylglutamate 5.96 × 10−11 Higher 0.0068 0.0545
Prolylglycine 5.96 × 10−11 Higher 0.2799 0.0676
Serylleucine 3.99 × 10−9 Higher 0.1903 0.0031
Seryltyrosine 1.61 × 10−7 Higher 0.4359 0.9654
Tyrosylglycine 2.38 × 10−10 Higher 0.0029 0.0044
Valylaspartate 9.51 × 10−8 Higher 0.0433 0.0031
Valylglycine 7.15 × 10−10 Higher 0.0355 0.8968
Valylleucine 1.16 × 10−8 Higher 0.3527 0.0014
Xenobiotics
Erythritol 4.07 × 10−8 Higher 0.1230 0.0009
Unknown
X – 11,677 8.28 × 10−9 Higher 0.0021 0.1728
X − 11,687 5.96 × 10−11 Higher 0.0068 0.8968
X − 11,787 2.71 × 10−5 Lower 0.3527 0.0831
X − 14,056 8.28 × 10−9 Higher 0.4813 0.7618
X − 14,603 4.11 × 10−6 Higher 0.0068 0.0067
X − 14,949 7.06 × 10−5 Lower 0.0007 0.0545
X − 15,546 5.96 × 10−11 Higher 0.0089 0.6334
X − 17,115 1.49 × 10−7 Higher 0.0866 0.6965
X − 19,411 1.53 × 10−7 Higher 0.2116 0.2370
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For example, previous reports indicate that TCA cycle 
metabolism, which we observed as lower in colon can-
cer cell lines, down-regulated in both tissue and plasma 
samples from patients with colorectal cancer [6, 8, 9, 14, 
27–32] (Figure 3b). Similarly, concordant with our analy-
sis of two ovarian cancer cell lines, higher levels of TCA 
cycle intermediates (including succinate, fumarate, and 
malate) have been observed in tissue samples from ovar-
ian carcinoma [8, 28].
The TCA cycle is connected to other metabolic path-
ways, including glycolysis, amino acid catabolism, and 
fatty acid synthesis; it is a central source of energy for 
healthy cells. In normal cellular metabolism, glucose is 
mainly catabolized into pyruvate, which is subsequently 
converted into acetyl-CoA and enters/supports the TCA 
cycle. In contrast, cancer cells primarily metaboliz glu-
cose into lactate. Therefore, in cancer cells the TCA cycle 
is not supported by the glycolytic pathway [33]. Thus the 
increased level of TCA intermediates in ovarian cancer 
cell lines suggests both impaired enzyme activity and the 
supplementation of the TCA cycle in those cell lines with 
molecules from other pathways (e.g., BCAA and AAA). 
Notably, alterations in the activity of TCA cycle enzymes, 
particularly succinate dehydrogenase (SDH) and fuma-
rate hydratase (FH), have been implicated in tumor 
susceptibility to chemotherapy [34, 35].Accumulated suc-
cinate and fumarate have been reported as intracellular 
messenger molecules that stabilize hypoxia-inducible 
factor (HIF), which in turn promotes the adaptation of 
cells to low-oxygen conditions and stimulates angio-
genesis [36, 37]. Furthermore, ovarian cancer cell lines 
exhibited higher levels of BCAA (isoleucine and valine) 
and AAA (phenylalanine and tyrosine), which can sup-
port the TCA cycle at the level of succinate and fumarate, 
Figure 3 Metabolic diversity in colon and ovarian cancer cell lines. a Synthetic view of the metabolic signatures of cell lines derived from colorectal 
and ovarian cancers. The full data presentation is available in Additional file 7: Figure S4 as box plots in a zoomable format. The blue color grada-
tion represents colon cancer cell lines (HCT15, dark blue; HCT116, light blue), red and orange indicate ovarian cancer cell lines (OVCAR3, red; SKOV3, 
orange). b Summary of the main findings of this study, as well as previously reported metabolomics changes observed in comparable human 
biofluids or tissue samples from patients with colon and ovarian carcinomas. Arrows indicate direction of changes reported in the literature and in 
the present study for colon and ovarian cancer cell lines.
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respectively. Elevated BCAA has been reported previ-
ously in fluid samples from malignant ovarian cysts [29]. 
Increased levels of both BCAA and AAA may be linked 
with alterations in the activity of their transporter, L-type 
amino acid transporter 1 (LAT1) [38], which has been 
recognized as an important molecule in the nutrition, 
proliferation, and migration of ovarian cancer cells [39].
In addition, we observed higher levels of FAs and GPLs 
in ovarian cancer cell lines. Because the TCA cycle pro-
vides building blocks (acetyl-CoA) for FA synthesis and 
elongation, it may justify the demand of increased TCA 
cycle metabolism observed in ovarian cancer cell lines. 
Furthermore, higher phosphatidylethanolamine and 
phosphatidylcholine levels suggest increases in the de 
novo synthesis of these GPLs, known as the Kennedy 
pathway [40]. Our observations are consistent with those 
of previous studies that reported increased glycerophos-
pholipids as a signature of ovarian cancer (Figure 3b) [8, 
14]. For instance, elevated phosphocholine is concordant 
with the previously reported enrichment of phospho-
choline in tissue samples from ovarian cancer patients 
[14]. Phosphatidylethanolamine can serve as a substrate 
for phosphatidylcholines, the extreme elevation of which 
has been reported previously in ovarian carcinomas [14]. 
Alteration in GPLs may be connected with their roles 
in membrane integrity and mitogenic signal transduc-
tion [41]. Furthermore, increased phosphatidylinositol 
has been associated with the deregulation of the phos-
phoinositide-3 kinase (PI3K) pathway, which in turn pro-
motes carcinogenesis and angiogenesis [42].
Colon cancer cell lines displayed higher levels of beta-
alanine and N-acetylputrescine. Significant elevation of 
the metabolite N-acetylputrescine has been reported 
previously in colorectal cancer tissue [9, 30]. A biogenic 
amine, N-acetylputrescine may be associated with urea 
cycle metabolism. Ornithine decarboxylase (ODC) is a 
first and rate-limiting factor in polyamine biosynthesis; it 
catalyzes the conversion of ornithine to putrescine [43], 
which is subsequently metabolized into N-acetylputres-
cine. Increased ODC activity in colorectal cancer has 
been reported [44]. Our observation of increased urea 
cycle rate and biogenic amines, as well as lower level of 
TCA cycle intermediates, is consistent with previous 
reports on tissue and biofluid samples from colon cancer 
patients [6, 30, 31, 45] (Figure 3b).
Lower levels of BCAA and AAA observed in colon 
cancer cell lines may be supported by a previous LC/MS-
based study that reported decreased plasma amino acids 
in patients with colorectal cancer [6]. However, a GC/
MS-based study of tissue samples from colorectal cancer 
reported increases in amino acid levels [30]. The differ-
ent technologies used might explain the discrepancies 
between the different studies. However, BCAA catabo-
lism may be associated with isovalerylcarnitine and 
isobutyrylcarnitine metabolism [46]; higher levels of both 
molecules were identified in colon cancer-derived cell 
lines, which further supports our findings.
The observation of significantly lower levels of GPLs 
and FAs in colon cancer cell lines is consistent with pre-
vious studies in human plasma [6] and tissue samples 
[30] (Figure  3b). Overall our observations suggest that 
in colon cancer cell lines, GPLs are hydrolyzed into FAs, 
which are then catabolized. The primary pathway for 
FAcatabolism is mitochondrial β-oxidation [47]. How-
ever, the mitochondrial membrane is impermeable to 
free FAs, FA transport across the mitochondrial mem-
brane requires a carnitine shuttle [47]. Accordingly, colon 
cancer cell lines exhibit higher levels of deoxy-carnitine, 
an intermediate in carnitine synthesis [48]. Colon cancer 
cell lines also exhibit higher levels of butyrylcarnitine and 
acylcarnitine, which may be associated with increased 
β-oxidation [49]. Notably, by undergoing beta-oxidation, 
FAs produce twice as much ATP as carbohydrates, which 
strongly support cancer function [50].
Conclusions and future directions
The main goal of this study was to examine metabolic 
diversity between colon and ovarian cancer cell lines. 
After further evaluation in clinical samples, this infor-
mation might enable clinicians to distinguish primary 
ovarian cancer from ovarian metastases of colorectal 
origin. Our study revealed 67 metabolites that signifi-
cantly differentiated colorectal from ovarian cancer cell 
lines, and may potentially be useful in cancer screen-
ing and diagnosis. Additionally, in this study we high-
lighted four pathways (out of hundreds) that should be 
extensively examined. The ovarian cancer cell lines were 
mainly characterized by elevated TCA cycle intermedi-
ates and elevated lipid synthesis. This information might 
assist novel drug design or drug repurposing, focus-
ing on enzymes/transporters involved in lipid and TCA 
cycle metabolism. In turn, the metabolic signatures of 
colon cancer cell lines suggest increased β-oxidation 
and increased urea cycle activity, which may indicate a 
demand for the removal of excess ammonia after rapid 
amino acid catabolism. These observations suggest that 
targeting β-oxidation and/or urea cycle metabolism in 
colon cancer might be successful strategies to control 
this neoplastic disease. Although there are incontestable 
benefits to the use of cell culture as a model system for 
metabolomics studies [10], additional investigations that 
employ primary cells and samples from malignant tissue 
and human biofluids are needed in order to validate and 
further refine the signatures reported in this study.
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